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Background: Korean ginseng, Panax ginseng Meyer, has been used as a traditional oriental medicine to
treat illness and promote health for several thousand years. Ginsenosides are the main constituents for
the pharmacological effects of P. ginseng. Since several ginsenosides, including ginsenoside (G)-Rg3 and
G-Rp1, have reported antiplatelet activity, here we investigate the ability of G-Rp4 to modulate adenosine
diphosphate (ADP)-induced platelet aggregation. The ginsenoside Rp4, a similar chemical structure of G-
Rp1, was prepared from G-Rg1 by chemical modiﬁcation.
Methods: To examine the effects of G-Rp4 on platelet activation, we performed several experiments,
including antiplatelet ability, the modulation of intracellular calcium concentration, and P-selectin
expression. In addition, we examined the activation of integrin aIIbb3 and the phosphorylation of
signaling molecules using ﬁbrinogen binding assay and immunoblotting in rat washed platelets.
Results: G-Rp4 inhibited ADP-induced platelet aggregation in a dose-dependent manner. We found that
G-Rp4 decreased calcium mobilization and P-selectin expression in ADP-activated platelets. Moreover,
ﬁbrinogen binding to integrin aIIbb3 by ADP was attenuated in G-Rp4-treated platelets. G-Rp4 signiﬁ-
cantly attenuated phosphorylation of extracellular signal-regulated protein kinases 1 and 2, p38, and c-
Jun N-terminal kinase, as well as protein kinase B, phosphatidylinositol 3-kinase, and phospholipase C-g
phosphorylations.
Conclusion: G-Rp4 signiﬁcantly inhibited ADP-induced platelet aggregation and this is mediated via
modulating the intracellular signaling molecules. These results indicate that G-Rp4 could be a potential
candidate as a therapeutic agent against platelet-related cardiovascular diseases.
Copyright  2016, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cardiovascular diseases (CVDs) are the highest cause of death in
Western and Asian countries due to epidemiological transition,
lifestyle changes, nutrition transition, and economic consequences
in the modernworld [1,2]. Recent studies have suggested that CVDs
are mainly caused by abnormal platelet activation and aggregation.
Atherosclerosis, one of the major CVDs, is a chronic inﬂammatory
disease in the arterial vessel wall, and thus, causing plague and
thrombus formation [3,4].
Platelets, derived from megakaryocytes of bone marrow, are
important factors relating to the progression of atherosclerosis.ysiology and Cell Signaling, College
ht  2016, The Korean Society of G
d/4.0/).Platelets play an essential role in hemostasis, thrombosis, inﬂam-
matory processes, atherosclerosis, and tumor metastasis [5e7].
When there is vascular injury, platelets exposed to subendothelial
matrix components including von Willebrand factor and collagen
trigger adhesion and activation [8]. Platelet activation leads to the
secretion of platelet granules including insulin-like growth factor 1,
platelet-derived growth factor, transforming growth factor-beta,
platelet factor 4, adenosine diphosphate (ADP), adenosine
triphosphate, and serotonin, which contain other platelet agonists
such as ADP, collagen, thrombin, and the generation of lipid-based
agonists such as thromboxane A2, resulting in an increase in
intracellular calcium ion ([Ca2þ]i) and platelet shape change. Theseof Veterinary Medicine, Kyungpook National University, Daehakro 80, Bukgu, Daegu
inseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
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cascade activation [9].
ADP plays an essential role in the process of hemostasis by
signaling through G-protein coupled receptors (GPCR), P2Y1 and
P2Y12 receptors. The Gq-coupled P2Y1 receptor plays a role in ADP-
induced platelet shape change. P2Y1 receptor signaling is impor-
tant for GPCR-mediated integrin activation, platelet granule
release, and consequently platelet aggregation [10]. In addition, Gi-
coupled-P2Y12 receptor induces platelet activation in the presence
of the GPCR agonist ADP. The role of P2Y12 receptors in promoting
platelet aggregation is consistent with inhibitory effects on cAMP,
which relieves the inhibitory effect of cAMP-dependent protein
kinase on platelet activation.
Korean ginseng (Panax ginseng Meyer) has been used as a
traditional Korean medicine. This folk medicine has been used to
treat illness and promote health for several thousand years [11].
The therapeutic potential of Korean ginseng has been discussed in a
multitude of in vitro and in vivo studies [12]. Recently ginseng’s
marvelous effects have been studied in awide range of pathological
conditions, such as CVDs, immune diseases, ischemic heart disease,
stroke, nervous disorders, and cancer [12]. Moreover, the ginseng-
mediated protective mechanism is reported to be due to antioxi-
dant, anti-inﬂammatory, antiaging, and antiapoptotic activity. In
addition, the antiplatelet activities by ginseng extracts and some
ginsenosides have also been determined [13,14]. However, infor-
mation on the effect of ginsenoside (G)-Rp4 on platelet activation is
limited. G-Rp4, a derivative from G-Rg1, is veriﬁed to be chemically
stable in comparison to G-Rg1.
In this study, the antiplatelet properties of G-Rp4 were inves-
tigated using ADP-stimulated platelet aggregation. We further
determined whether G-Rp1 affected intracellular downstream
signal transductions (i.e., intracellular calcium ion concentration,
granule secretions, signaling molecule phosphorylation, and
ﬁbrinogen binding to active integrin aIIbb3).
2. Materials and methods
2.1. Materials
G-Rp4 with 99% purity was obtained from Ambo Institute
(Seoul, Korea). ADPwas purchased from Chronolog (Havertown, PA,
USA). Fura-2-acetoxymethyl ester (Fura-2/AM) was procured from
SigmaeAldrich Co. (St. Louis, MO, USA). Mouse monoclonal to
CD62P antibody and goat polyclonal to mouse immunoglobulin (Ig)
G-H&L (ﬂuorescein isothyocianate) antibodies were gained from
Abcam (Cambridge, UK). Alexa Fluor488 ﬁbrinogen conjugate was
fromMolecular Probes (Eugene, OR, USA). All other chemicals were
of reagent grade. Antibodies of phospho-extracellular signal-regu-
lated kinase-2 (ERK2; p44/42), total-ERK2 (p44/42), phospho-p38,
total-p38, phospho-c-Jun N-terminal kinase (JNK), total JNK,
phospho-protein kinase B (Akt), total Akt, phospho-
phosphatidylinositol 3-kinase (PI3K; p85/p55), and PI3K (p85),
phospho-phospholipase C (PLC)-g, total PLCg, were purchased from
Cell Signaling (Beverly, MA, USA).
2.2. Washed rat platelet preparation
Male Sprague Dawley 8e10-wk old rats (240e250g) were ac-
quired from Orient Co. (Seoul, Republic of Korea). The rats were
maintained in a standard laboratory animal facility with free access
to food and water and they were acclimatized to these conditions
for at least 1 wk before use. Whole blood from the rats was
collected using a 23G needle inserted into the left ventricle of the
heart and then transferred to a 14-mL round test tube including
1 mL of acid citrate dextrose solution (85mM trisodium citrate,83mM dextrose, and 21mM citric acid) as an anticoagulant.
Platelet-rich plasma (PRP) was prepared by centrifugation of the
whole blood samples at 350 g for 7 min twice at room temperature,
and the PRP was washed with washing buffer (Tyrode buffer 4).
Washed platelets were then tenderly resuspended in Tyrode buffer
(137mM NaCl, 12mM NaHCO3, 5.5mM glucose, 2mM KCl, 1mM
MgCl2, 0.3mM NaHPO4, pH 7.4) to a ﬁnal concentration of 3  108
platelets/mL [15].
2.3. Platelet aggregation in vitro assay
Platelet aggregation was performed as previously described
[16,17]. PRP (3  108 platelets/mL) was preincubated for 2 min at
37C in the presence of 1mM exogenous CaCl2 with various con-
centrations (6.25e50mM) of G-Rp4 and then platelet aggregation
was encouraged by ADP (10mM). The reaction mixture was further
incubated for 5 min with stirring at 250 g. The concentration of the
vehicle was held at < 0.05%. The aggregation was monitored using
an aggregometer (Chronolog, Havertown, PA, USA) at a constant
stirring of 250 g and aggregation rates were measured as the light
transmission changes were recorded for 9 min.
2.4. [Ca2þ]i measurement
The [Ca2þ]i was measured with Fura-2/AM as previously
described [15]. Brieﬂy, the washed platelets were incubated with
Fura-2/AM (5mM) for 30 min at 37C and platelet aggregation assay
was done using the washed platelets. The Fura-2-loaded platelets
(3  108/mL) were then preincubated with G-Rp4 for 2 min at 37C
in the presence of 1mM CaCl2, and subsequently stimulated with
ADP for 5 min. Fluorescent signals were recorded using a F-2500
ﬂuorescence spectroﬂuorometer (Hitachi, Ltd., Tokyo, Japan). Light
emission was measured at 510 nm with simultaneous excitation at
340 nm and 380 nm that changed every 0.5 s. Fura-2 ﬂuorescence
in the cytosol measured with the spectroﬂuorometer was calcu-
lated as previously described [18,19].
2.5. Determination of P-selectin expression
Washed platelets, treated with various concentrations (6.25e
50mM) of G-Rp4 or vehicle were stimulated with ADP (10mM) and
incubated at 37C for 5 min. The reaction was discontinued, and
platelets were centrifuged consecutively and resuspended in cool
phosphate-buffered saline (PBS), containing 10% fetal bovine serum
and 1% sodium azide. Platelets were then incubated with CD62P
primary antibody in 3% bovine serum albumin/PBS for 30 min at
4C in the dark. Next, platelets were ﬁxed using 0.5% para-
formaldehyde and washed three times by centrifugation at
2,000 g for 5 min and resuspended in cool PBS one after another.
Fluorescein isothyocianate-conjugated secondary antibody was
incubated in 3% bovine serum albumin/PBS for 30 min at 4C in the
dark. Flow cytometry analysis was performed on a FACSAria III ﬂow
cytometer using CellQuest software (Becton Dickinson Immuno-
cytometry Systems, San Jose, CA, USA) [11].
2.6. Determination of ﬁbrinogen binding to integrin aIIbb3
Washed platelets were at ﬁrst treated with G-Rp4 or vehicle and
incubated for 5 min at room temperature. Then, 10mM ADP was
added together with 200 mg/mL Alexa Fluor 488-human ﬁbrinogen
(Molecular Probes, Eugene, OR, USA), and the sample was incu-
bated at 37C for 15 min. Alexa Fluor 488-ﬁbrinogen binding to
platelets was determined by ﬂow cytometry using FACSAria III ﬂow
cytometer (Becton Dickinson Immunocytometry Systems), and
Fig. 2. Effect of ginsenoside (G)-Rp4 in adenosine diphosphate (ADP)-activated [Ca2þ]i
concentration. Washed platelets (3  108/mL) were incubated with or without a G-Rp4
in the presence of 1mM CaCl2 at 37C for 2 min. The platelets were stimulated with
ADP (10mM) at 37C for 3 min. Intracellular calcium ion was then determined with a
spectroﬂuorometer as described in the Materials and methods section. *p < 0.001
versus ADP-stimulated control. [Ca2þ]I, intracellular calcium ion.
J Ginseng Res 2017;41:96e10298data were analyzed using CellQuest software (Becton Dickinson
Immunocytometry Systems) [11].
2.7. Immunoblotting
Platelets (5  108/mL) were activated with ADP for 5 min in the
presence of 1mM CaCl2 with G-Rp4 (6.25e50mM) and instantly
dissolved in sample buffer (0.125M Tris-HCl at pH 6.8, 2% fetal
bovine serum, 2% b-mercaptoethanol, 20% glycerol, 0.02% bromo-
phenol blue in the present of 1mM phenylmethylsulfonylﬂuoride,
2 mg/mL aprotinin, 1 mg/mL leupeptin, and 1 mg/mL pepstatin).
Protein concentrationwas measured using bicinchoninic acid assay
(PRO-MEASURE, iNtRON Biotechnology, Kyungki-Do, Korea) on ice.
After boiling for 5 min, the proteins were resolved by electropho-
resis in 10% sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and then transferred to polyvinylidene
diﬂuoride (PVDF) membranes in a transfer buffer [25mM Tris (pH
8.5) and 20% methanol]. The membrane was blocked with 5% skim
milk, washed, and subjected to immunoblotting with ERK1/2, p38
JNK, Akt, PI3K, PLCg antibodies. The immunoblots were again
incubated with horseradish peroxidase secondary antibody and the
membranes were visualized using enhanced chemiluminescence
(iNtRON Biotechnology).
2.8. Statistical analysis
Data were analyzed by one-way analysis of variance, using SAS
version 9.1 (SAS Institute Inc., Cary, NC, USA) tool, followed by a post
hoc Dunnett’s test in order to determine the statistical signiﬁcance
of the differences between treatment groups. All data are presented
as means  standard deviation, and p < 0.05 were considered to
statistically signiﬁcant.
3. Results
3.1. Inhibitory effect of G-Rp4 on ADP-induced platelet aggregation
The concentration of ADP (10mM) could induce full activation
and aggregation in rat washed platelets. Therefore, 10mM of ADP
was used as the ligand to induce platelet aggregation in the further
studies. While washed platelets were strongly activated by 10mM of
ADP in the presence of 1mM CaCl2, G-Rp4 signiﬁcantly reduced
ADP-induced platelet aggregation in a concentration-dependent
manner with an IC50 of 30.86  0.12mM (Fig. 1B). However, G-Rg1A B
Fig. 1. The inhibitory effect of ginsenoside (G)-Rp4 on adenosine diphosphate (ADP)-induce
Rg1 (100mM) and G-Rp4 (50mM) in the presence of 1mM CaCl2 at 37C for 2 min. (B) Platelet
of 1mM CaCl2 at 37C for 2 min. The platelet aggregation was induced by 10mM of ADP, a
gregation reactionwas completed after 5 min, and the percent aggregation rate was calculate
the mean  standard deviation of at least three independent experiments. *p < 0.001 vershas not shown any antiplatelet activity in ligand-induced platelet
aggregation (Fig. 1A).
3.2. G-Rp4 reduces ADP-induced [Ca2þ]i mobilization
The release of granule contents boosts platelet activation signals
and is considered to be an important indicator of the platelet-
activating cascade. [Ca2þ]i concentration plays an essential role in
platelet aggreagtion such as platelet activation and thrombus for-
mation. Thus, we investigated the effects of G-Rp4 on ADP-induced
[Ca2þ]i mobilization. Pretreatment of the washed platelets with the
various concentration of G-Rp4 (6.25e25mM) remarkably pre-
vented the rise in ADP-stimulated [Ca2þ]i (Fig. 2).
3.3. G-Rp4 inhibits P-selectin expression in ADP-activated platelets
Since granule secretions are important markers of platelet
activation in the earlier phase of platelet aggregation, we deter-
minedwhether G-Rp4 preincubation affected the granule release ind platelet aggregation. (A) Platelets (3  108/mL) were preincubated with or without G-
s (3  108/mL) were preincubated with or without G-Rp4 (6.25e50mM) in the presence
nd the extent of aggregation was determined with chrono-log aggregometer. The ag-
d. The bar graphs are a summary of four independent experiments. Each column shows
us ADP-activated control.
Fig. 3. Effect of ginsenoside (G)-Rp4 on adenosine diphosphate (ADP)-activated P-selectin expression. Washed platelets (3  108/mL) were incubated with or without a G-Rp4
(6.25e25mM) in the presence of 1mM CaCl2 at 37C for 2 min. The platelets were stimulated with adenosine diphosphate (10mM) for 3 min at 37C. (A) Flow cytometry analysis was
performed on a FACSAria III ﬂow cytometer using CellQuest software. (B) The data are presented as mean  standard deviation of three independent experiments. *p < 0.01.
**p < 0.001 versus ADP-activated control. FITC, ﬂuorescein isothiocyanate.
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remarkable and concentration-dependently reduced in G-Rp4
treated platelets (Figs. 3A and 3B). It showed that platelet a-granule
secretory activity was signiﬁcantly and dose-dependently impaired
by G-Rp4 pretreatment.3.4. G-Rp4 reduces ﬁbrinogen binding to activated integrin-aIIbb3
The ligation of integrin-aIIbb3 function is the principal conse-
quence of activation and adhesion in platelets and then aggregation
as a result of the adhesive substrates bound to the membranes of
activated platelets. Therefore, we determined the function of G-Rp4
on the response mechanism in integrin aIIbb3 activation. ADP-
stimulated ﬁbrinogen binding to its receptor was concentration-
dependently inhibited in various G-Rp4-treatmented platelets(Fig. 4). As expected, ethylene glycol tetra-acetic acid (10mM)
signiﬁcantly blocked ﬁbrinogen binding to active integrin-aIIbb3
[20]. This result suggested that G-Rp4 may impair integrin-aIIbb3
conformational changes for high correspondence ﬁbrinogen bind-
ing site exposure (inside-out signaling) that arises as a result of
prior platelet agonist interactions [21e23]. The next step of
outside-in signaling implies a number of intracellular effectors,
which is essentially associated with the integrin b3 subunit, PLCg
and PI3K [24e26].3.5. G-Rp4 suppresses ADP-stimulated platelet mitogen-activated
protein kinases phosphorylations
The antiplatelet effect is known to inhibit phosphorylation of
mitogen-activated protein kinases (MAPKs; p38 MAPK, ERK, and
Fig. 4. Ginsenoside (G)-Rp4 reduces ﬁbrinogen binding to activated integrin-aIIbb3.
The inhibitory effect of G-Rp4 in ﬁbrinogen binding to integrin-aIIbb3 in adenosine
diphosphate (ADP)-stimulated platelets was examined using ﬂow cytometry analysis.
Washed platelets (3  108/mL) were pretreated CaCl2 1mM with or without G-Rp4 at
37C for 2 min and then the platelets were added to 10mM ADP with Alexa Fluor 488-
human ﬁbrinogen (200 mg/mL), and the sample was incubated at 37C for 15 min. The
bar graphs shows the mean  standard deviation of three independent experiments.
*p < 0.05. **p < 0.001 versus ADP-activated control. EGTA, ethylene glycol tetra-acetic
acid.
J Ginseng Res 2017;41:96e102100JNK) and is also reported to be phosphorylated by various platelet
agonists [27e30]. Thus, we experimented whether G-Rp4 could
modulate MAPKs. Our ﬁndings showed that G-Rp4 signiﬁcantly
inhibited ADP-induced ERK1/2, JNK, and p38 MAPKs signaling
pathway in a concentration-dependent manner (Figs. 5A and 5B).
3.6. G-Rp4 inhibits the phosphorylation of PLCg and PI3K/AKT
proteins involved in platelet glycoprotein signaling
PI3K plays a remarkable role in plateleteADP receptor signaling
pathway. Platelet glycoproteins and the activation of PLCg is sig-
niﬁcant for the most part of functional reactions to ADP, containing
aggregation and alpha-granule secretion, so here we demonstrated
the effect of G-Rp4 on the expression levels of the indicated pro-
teins [31]. G-Rp4 suppressed ADP-stimulated PLCg and PI3K/AKT
phosphorylation in a dose-dependent manner (Fig. 6).A B
Fig. 5. Effects of ginsenoside (G)-Rp4 on adenosine diphosphate (ADP)-stimulated phospho
were incubated for 2 min at 37C with vehicle or G-Rp4 at the indicated concentration in th
ADP for 5 min at 37C. After completing the responses, total platelet proteins were extrac
trophoresis and transferred onto polyvinylidene ﬂuoride membranes. (A) The membranes w
regulated kinases 1 and 2 (ERK1/2), p38, stress-activated protein kinases/Jun amino-term
munoblots are representative of three or four independent experiments. (B) The bar grap
*p < 0.05. **p < 0.001 versus control.4. Discussion
Ginseng contains saponins, proteins, amino acids, nucleic acids,
fatty acid components, essential oils, polyacetylenes, phenolic
compounds, terpenoids, and various other components. Among
them, ginsenosides are the pharmacologically active components
found in ginseng that are classiﬁed into 20(S)-protopanaxatriols
such as Re and Rg1 and 20(S)-protopanaxdiols like Rg2 and Rh1,
according to a site of glycoside [32].
Until now, research on ginseng has been carried out in order to
investigate its pharmacological efﬁcacy and various other medical
and biological aspects. Ginsenosides are known to exhibit various
effects by acting on physical functions such as central nervous,
endocrine, immune, and metabolic systems [11,33e35]. Among
these ginsenosides, Rg1 was reported to be efﬁcacious for antifa-
tigue and memory progression. Besides, G-Rp1 derived from G-Rg3
was reported to be potent in antiplatelet activity, but information
on the effect of the stable compound G-Rp4 derived from G-Rg1 on
platelet activation is limited. Therefore, we ﬁrst examined whether
G-Rp4 affected ADP-induced platelet aggregation, and then inves-
tigated its molecular mechanism of antiplatelet activity by
analyzing downstream signal transduction (e.g., [Ca2þ]i mobiliza-
tion, P-selectin secretion, MAPK and PI3K/Akt phosphorylation, and
ﬁbrinogen binding to active integrin a-IIbb3).
Previous reports showed that G-Rp1 has potent antiplatelet
activity through the mechanisms of PI3K, PLCg, MAPKs, and
phosphorylation of vasodilator-stimulated phosphoprotein by
increasing cAMP [11]. In the present study, we have shown that G-
Rp4 mediates its antiplatelet activity by phosphorylation of PLCg,
PI3K, Akt, and MAPKs through signaling of GPCR P2Y12 binding to
ADP.
Platelets, also called thrombocytes, are small, irregular-shaped
blood cells derived from megakaryocytes that serve diverse roles
in different pathological or physiological pathways in hemostasis
and inﬂammation [13]. Platelet activation and aggregation occurs
via many biochemical and biophysical pathways. Platelet agonists,
such as collagen, ADP, thrombin, and thromboxane A2, activate
platelets through GPCR pathways [36]. Platelets are usually present
in the inactive state, but activationwith agonists like collagen, ADP,
thrombin, and thromboxane A2 turn on the active state of platelets
[37]. Platelet aggregation occurs whenmembrane receptors bind torylation of mitogen-activated protein kinases (MAPKs). Washed platelets (3  108/mL)
e presence of 1mM CaCl2 with stirring. The platelets were then stimulated with 10mM
ted. The proteins were separated by sodium dodecyl sulfate polyacrylamide gel elec-
ere then investigated with antibodies against total and phospho-extracellular-signal-
inal kinases (JNK). Antibody binding was visualized with chemiluminescence. All im-
h shows the mean  standard deviation of three or four independent experiments.
p-Akt
Akt
A B
Fig. 6. Effects of ginsenoside (G)-Rp4 on adenosine diphosphate (ADP)-stimulated phosphorylation of phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), and phospholipase
C-g (PLCg). Washed platelets (3  108/mL) were preincubated at 37C for 2 min with vehicle or various concentration of G-Rp4. The platelets were then stimulated with 10mM ADP
at 37C for 5 min. After completing the reactions, total platelet proteins were extracted. The proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis
and transferred onto polyvinylidene ﬂuoride membranes. (A) The membranes were then incubated with antibodies against phospho-PLCg, phospho-PI3K, and phospho-Akt.
Antibody binding was visualized with chemiluminesence. (B) The bar graph shows the mean  standard deviation of three or four independent experiments. *p < 0.05.
**p < 0.01. ***p < 0.001 versus vehicle control.
Fig. 7. The schematic diagram for possible inhibitory activity of ginsenoside Rp-4 on
adenosine diphosphate (ADP)-induced platelet aggregation. Akt, protein kinase B; G,
ginsenoside; MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide 3-
kinase.
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due to the activation of various signal transduction factors. With
the binding of ADP to P2Y1 receptors, Gq protein target and activate
PLC which cleavage phosphatidylinositol 4,5-bisphosphate into
inositol triphosphate and diacylglycerol. The resulting inositol
triphosphate causes an increase in the [Ca2þ]i level in platelets [10].
Subsequently, platelet shape change is caused by contraction of
cytoskeletal protein. However, diacylglycerol and calcium work in
conjunction causing the increased level of PKC which goes on to
phosphorylate other molecules involved in platelet cellular activity.
In this cellular cascade, platelet activation facilitates platelet ag-
gregation and granule secretion in the platelets. Here, we
conﬁrmed that [Ca2þ]i concentration and P-selectin expression are
increased when platelets are treatedwith ADP, which was inhibited
with G-Rp4 treatment. Since granule release is known to occur in
the early phase of platelet activation and aggregation [38,39], this
indicated that G-Rp4 affected the initial stage of platelet activation.
In this study, we demonstrated that G-Rp4 remarkably inhibited
ADP-stimulated MAPK phosphorylation (e.g., ERK1/2, JNK, and p38
MAPK), suggesting that MAPK signalingmay be involved in G-Rp4’s
antiplatelet activity. It was well known that ERK1/2 cascade in
platelet activation was involved in the [Ca2þ]i mobilization in ADP-
stimulated platelets. Moreover, it is well-established that JNK and
p38 MAPK signaling play an important role in stimulating granule
secretion and integrin aIIbb3 activation agonist-induced platelet
aggregation and thrombus formation [40,41]. This is the case with
PI3K/Akt signaling in agonist-activated platelet aggregation. PI3K/
Akt is involved in the ligand-stimulated platelet activation, which
was mediated via PI3K/Akt-nitric oxide synthase-cyclic guanosine
monophosphate (GMP) axis [42]. Although we have yet to deter-
mine the involvement of nitric oxide-cyclic GMP, we inferred to the
participation of PI3K/Akt-cyclic GMP pathway in G-Rp4-mediated
antiplatelet activity. Interestingly, G-Rp4 markedly inhibited
integrin-aIIbb3 activation in ADP-stimulated platelets (Fig. 3).
Platelet integrin-aIIbb3 could bind to multiple ligands, such as
ﬁbrinogen, ﬁbronectin, and von Willebrand factor, which mediates
outside-in signaling and is the ﬁnal step in platelet activation and
aggregation [43,44]. The blocking of integrin-aIIbb3 activation is a
fascinating target in clinical antiplatelet pharmacology [45,46].
Therefore, G-Rp4 could be a candidate of antiplatelet therapeutic
for inhibiting the outside-in signaling of integrin-aIIbb3 directly or
indirectly, which remains to be clariﬁed (Fig. 7).In conclusion (Fig. 7), this study indicates that the inhibitory
effect of G-Rp4 occurs in a concentration-dependent manner in
ADP-induced platelet aggregation. In addition, G-Rp4 markedly
suppressed intracellular downstream signal transduction (i.e.,
granule secretion and the phosphorylation of signaling molecule
proteins). That is, G-Rp4 signiﬁcantly inhibited ADP-induced [Ca2þ]i
mobilization and P-selectin expression. Furthermore, we found that
G-Rp4 notably inhibited the phosphorylation of all three MAPKs
(i.e., ERK1/2, JNK, and p38 MAPK) and PI3K/Akt phosphorylation.
Finally, integrin-aIIbb3 activation, the ﬁnal step of full platelet
activation, was remarkably suppressed by G-Rp4 pretreatment.
Based on our present results, we suggest that G-Rp4 showed an-
tiplatelet activity via the modulation of intracellular downstream
J Ginseng Res 2017;41:96e102102signaling components. Therefore, G-Rp4 can be regarded as a po-
tential therapeutic agent for preventing CVDs, such as thrombosis
and ischemia.
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